Arcutis Q1 net product revenue $2.8M; net loss $80.1M as ZORYVE launch builds

Arcutis Biotherapeutics, Inc.

2023-Q1 EPS reported -$1.31 revenue$2,781,000

Net product revenue of $2.8M from ZORYVE; unit demand nearly doubled QoQ.
Net loss $80.1M ($1.31/share) vs $64.3M ($1.27) in Q1 2022; SG&A rose to $42.9M.
Cash, equivalents, and marketable securities $333.3M; operating cash burn $80.3M in Q1.
Health Canada approved ZORYVE for plaque psoriasis; launch expected in coming weeks.
FDA accepted NDA for roflumilast foam (seborrheic dermatitis); target action date Dec 16, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arcutis Biotherapeutics, Inc. reported the quarter ended March 31, 2023 results: revenue $2.8 million.

Period: the quarter ended March 31, 2023
Revenue: $2.8 million
Result: reported results

Exact text from the filing

by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update • Achieved net revenues of $2.8 million for ZORYVE® (roflumilast) cream 0.3% in the first quarter of 2023, with unit demand growth nearly doubling quarter-over-quarter • Continued expansion of commercial payer coverage

View on SEC.gov

Browse all earnings releases →

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001787306-23-000042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.